WNT signaling drives cholangiocarcinoma growth and can be pharmacologically inhibited-Reference-Cited by-同舟云学术

WNT signaling drives cholangiocarcinoma growth and can be pharmacologically inhibited

Published:2015-02-17 Issue:3 Volume:125 Page:1269-1285
ISSN:0021-9738
Container-title:Journal of Clinical Investigation
language:en
Short-container-title:J. Clin. Invest.

Author:

Boulter Luke,Guest Rachel V.,Kendall Timothy J.,Wilson David H.,Wojtacha Davina,Robson Andrew J.,Ridgway Rachel A.,Samuel Kay,Van Rooijen Nico,Barry Simon T.,Wigmore Stephen J.,Sansom Owen J.,Forbes Stuart J.

Publisher

American Society for Clinical Investigation

Subject

General Medicine

Reference68 articles.

1. Crypt stem cells as the cells-of-origin of intestinal cancer

2. Inhibition of the Wnt palmitoyltransferase porcupine suppresses cell growth and downregulates the Wnt/β-catenin pathway in gastric cancer

3. Can we safely target the WNT pathway?

4. Changing international trends in mortality rates for liver, biliary and pancreatic tumours

5. Changing pattern of epidemiology in intrahepatic cholangiocarcinoma

Cited by 222 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Targeting the Wnt/β-catenin signal pathway for the treatment of gastrointestinal cancer: Potential for advancement;Biochemical Pharmacology;2024-09

2. Overcoming treatment resistance in cholangiocarcinoma: current strategies, challenges, and prospects;Frontiers in Cell and Developmental Biology;2024-08-02

3. Novel Adiponectin Receptor Agonist Inhibits Cholangiocarcinoma via Adenosine Monophosphate-activated Protein Kinase;Current Medicinal Chemistry;2024-08

4. The Tumor Immune Microenvironment plays a Key Role in Driving the Progression of Cholangiocarcinoma;Current Cancer Drug Targets;2024-07

5. Tumor-associated macrophages in anti-PD-1/PD-L1 immunotherapy for hepatocellular carcinoma: recent research progress;Frontiers in Pharmacology;2024-06-18